Company profile

Sana Biotechnology

Sana Biotechnology, founded in 2018, joined the Unicorn Club in June 2020 after raising an $821 million Series D led by F-Prime Capital, Arch Venture Partners, Flagship Pioneering, and others. Headquartered in Seattle, Washington, United States, the biotech startup has raised $821 million across five funding rounds. Sana develops genetically engineered cell therapies for oncology, diabetes, and CNS disorders using gene therapy and gene editing approaches. Investors include F-Prime Capital, Arch Venture Partners, Flagship Pioneering, HTIF, and Baillie Gifford. Funding supports clinical programs, pipeline expansion, and scalable manufacturing.